Related Experiment Video
Updated: Nov 12, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Sequential therapies for advanced urothelial cancer: Hope meets new challenges
Daniel Herchenhorn1, Vinicius Freire2, Thamires Oliveira2
1Grupo de Oncologia D'Or, Instituto D'Or de Ensino e Pesquisa, Brazil; Latin America Cooperative Oncology Group - LACOG, Brazil.
Abstract:
A dramatic change in the treatment of advanced urothelial carcinomas (UC) occurred in the last 3 years, initially with the development of several check-point inhibitors, for second and first-line therapy. More recently, the approval of anti-FGFR (Fibroblast Growth Factor Receptor) and anti-nectin-4 inhibitors based on phase 2 studies in refractory disease, and the preliminary results of 3 randomized phase 3 trials combining chemotherapy and immunotherapy in first-line as well as using maintenance immunotherapy after chemotherapy induction, created a new paradigm in the treatment of metastatic disease. In this review, we will explore the new classes of agents and how they could be incorporated in the clinical practice as well as the results of recently presented randomized studies, guiding oncologists on the possible sequences for patients with advanced urothelial carcinoma.
Insights
Recent advances in urothelial carcinoma (UC) treatment include new immunotherapies and targeted agents like anti-FGFR and anti-nectin-4 inhibitors. This review guides oncologists on integrating these novel therapies for advanced UC.
Area of Science:
- Oncology
- Urothelial Carcinoma Research
- Medical Treatment Advancements
Background:
- Advanced urothelial carcinoma (UC) treatment has seen significant evolution.
- The last three years introduced immune check-point inhibitors for first and second-line therapies.
Purpose of the Study:
- To review new classes of agents for advanced UC.
- To explore the integration of novel therapies into clinical practice.
- To guide oncologists on treatment sequencing for metastatic UC.
Main Methods:
- Review of recent clinical trial data.
- Analysis of preliminary results from randomized phase 3 trials.
- Exploration of novel therapeutic agents including anti-FGFR and anti-nectin-4 inhibitors.
Main Results:
- Approval of anti-FGFR and anti-nectin-4 inhibitors for refractory disease.
- Positive preliminary results from randomized trials combining chemotherapy and immunotherapy.
- Emergence of maintenance immunotherapy strategies post-chemotherapy induction.
Conclusions:
- A new treatment paradigm for metastatic urothelial carcinoma has been established.
- Novel agents and treatment combinations are reshaping clinical practice.
- Evidence-based guidance is provided for sequencing advanced UC therapies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Urinary Tract Calculi VI: Surgical Management

